ADRB2 and cancer: Cox and co-workers reported in a series of publications that the ADRB2 agonists epinephrine and isoproterenol caused a rise in the intracellular cAMP levels, followed by increased activity of cAMP-dependent PKA and a higher number of neuroendocrine-like cancer cells (70, 84).